Feb 20 - Artificial intelligence giant OpenAI lost a bid on Thursday to dismiss a lawsuit in New York federal court alleging it misused news articles published by The Intercept to train its popular ...
Intercept's Ocaliva approval in jeopardy after FDA flags concerns in advisory committee briefing doc
For Intercept Pharmaceuticals’ beleaguered liver disease drug Ocaliva, the hits just keep coming. Ahead of an advisory committee meeting slated for Friday, the FDA on Wednesday unleashed damning ...
While the path for any drug to go from lab research to commercialization takes years, Intercept Pharmaceuticals now stands as another example that a product’s market exit can also be long and winding.
Please provide your email address to receive an email when new articles are posted on . Intercept has voluntarily withdrawn its lone product, Ocaliva, from U.S. market for primary biliary cholangitis.
After a long run of regulatory stumbles and the recent withdrawal of its lone commercial drug from the U.S. market, Intercept Pharmaceuticals is implementing a restructuring and rounds of job cuts in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback